Marco Vito Marino1, Francesco Giovinazzo2, Mauro Podda3, Marcos Gomez Ruiz4, Manuel Gomez Fleitas5, Adolfo Pisanu3, Mario Adelfio Latteri6, Kyoichi Takaori7. 1. Department of Emergency and General Surgery, Azienda Ospedaliera, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy; Department of General and Digestive Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Department of Surgical, Oncological and Oral Science, Palermo University Hospital, Palermo, Italy; General Surgery Department, Policlinico Abano Terme, Padova, Italy. Electronic address: marco.marino@casacura.it. 2. Department of Surgery, Transplantation Service, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. 3. Department of Surgery, Cagliari University Hospital D. Casula, Cagliari, Italy. 4. Department of General and Digestive Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 5. Department of Robotics and Surgical Innovation, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 6. Department of Surgical, Oncological and Oral Science, Palermo University Hospital, Palermo, Italy. 7. Department of General Surgery, Kyoto University Hospital, Shogoin, Sakyo-ku, Kyoto, Japan.
Abstract
BACKGROUND: Despite the potential benefits, the adoption of the minimally invasive surgery for the treatment of borderline resectable pancreatic cancer is still in the initial phase. We investigated the safety and feasibility of the robotic pancreaticoduodenectomy with venous resection/reconstruction (RPD SMV/PV). METHODS: Since March 2013 to October 2019, a total of 73 RPD and 10 RPD SMV/PV were performed. The two groups were case-matched according to the preoperative characteristics. RESULTS: Mean operative times and estimated blood loss were less in the RPD group in comparison to that in the RPD with SMV-PV group (525 vs 642 min, p = 0.003 and 290 vs 620 ml, p = 0.002, respectively). The mean length of hospital stay was similar in the RPD group in comparison to that in the RPD with SMV-PV group (10 days vs 13 days, p = 0.313). The two groups had similar overall postoperative morbidity rate (57.5% vs 60%, p = 0.686), although the severe complication rate was lower in the RPD group (11% vs 40%, p = 0.004). CONCLUSIONS: RPD with SMV-PV is associated with increased operative time, estimated blood loss, higher major complication rate compared with RPD.
BACKGROUND: Despite the potential benefits, the adoption of the minimally invasive surgery for the treatment of borderline resectable pancreatic cancer is still in the initial phase. We investigated the safety and feasibility of the robotic pancreaticoduodenectomy with venous resection/reconstruction (RPD SMV/PV). METHODS: Since March 2013 to October 2019, a total of 73 RPD and 10 RPD SMV/PV were performed. The two groups were case-matched according to the preoperative characteristics. RESULTS: Mean operative times and estimated blood loss were less in the RPD group in comparison to that in the RPD with SMV-PV group (525 vs 642 min, p = 0.003 and 290 vs 620 ml, p = 0.002, respectively). The mean length of hospital stay was similar in the RPD group in comparison to that in the RPD with SMV-PV group (10 days vs 13 days, p = 0.313). The two groups had similar overall postoperative morbidity rate (57.5% vs 60%, p = 0.686), although the severe complication rate was lower in the RPD group (11% vs 40%, p = 0.004). CONCLUSIONS: RPD with SMV-PV is associated with increased operative time, estimated blood loss, higher major complication rate compared with RPD.
Authors: Pasquale Scognamiglio; Björn-Ole Stüben; Asmus Heumann; Jun Li; Jakob R Izbicki; Daniel Perez; Matthias Reeh Journal: Visc Med Date: 2021-11-12